PLN R14del Cardiomyopathyにおける補償メカニズムと潜在的な治療目標としての展開タンパク質応答
Dries A M Feyen1,2, Isaac Perea-Gil1,3, Renee G C Maas4
1Cardiovascular Institute, Stanford University, CA (D.A.M.F., I.P.-G., J.A.A., N.V., M.V., P.L.A., K.S., M.M., I.K.).
Circulation
|April 30, 2021
まとめ
展開タンパク質反応 (UPR) は,フォスフォランブ R14del心臓病において保護的である. UPRを活性化することで この心臓病の新たな治療法が 提供されるかもしれません
科学分野:
- 心血管生物学
- 分子心臓科
- 幹細胞生物学
背景:
- フォスフォランバン (PLN) R14del変異は拡張性心筋病と心律乱を引き起こす.
- PLN R14del心筋病の原因となる正確なメカニズムは不明である.
- 現在,PLN R14del心筋病に対する標的治療法はありません.
研究 の 目的:
- 人間の誘発性多能幹細胞 (hiPSC-CMs) を用いて,PLN R14del心筋病の分子メカニズムを調査する.
- 特定された病気の経路を標的とした潜在的な治療戦略を探求する.
主な方法:
- 疾患メカニズムを特定するために,hiPSC-CMで単細胞RNA配列を解析した.
- 2Dと3Dの収縮性アッセイを用いて心臓機能を評価した.
- 展開されたタンパク質応答 (UPR) の作用を調査し,治療的介入としてUPR活性化剤 (BiP誘導体X) を試験した.
主要な成果:
- PLN R14del hiPSC-CMは収縮性欠陥を示し,疾患のフェノタイプを再現した.
- 単細胞RNA配列解析は,PLN R14delモデルと患者の心臓でUPRの活性化を示した.
- UPR経路の静止は収縮機能障害を悪化させ,BiP誘導体X治療は投与量に依存して欠陥を改善した.
結論:
- 展開されたタンパク質反応 (UPR) は,PLN R14del心筋病症において保護的役割を果たします.
- UPRの調節は,PLN R14delに関連した心臓病の治療に有望な治療法です.
関連する概念動画
01:37The Unfolded Protein Response
5.7K
The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
5.7K
01:31Regulation of the Unfolded Protein Response
2.8K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.8K
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
162
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
162
01:30Cardiomyopathy II: Dilated Cardiomyopathy
118
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
118
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.3K
01:29Heart Failure II: Pathophysiology
153
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
153